ALXN Stock News 161.10 05/13/2014 07:25:06 Alexion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

May 13, 2014 at 8:25 AM

Alexion Pharmaceuticals (ALXN) 161.10 $ALXN

Alexion Pharmaceuticals Rises 5.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 5:08PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $153.14 to a high of $161.52. Yesterday, the shares gained 5.4%, which took the trading range above the 3-day high of $158.46 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Post Earnings Update: Alexion Pharmaceuticals Has Sunk 2.0% Lower in Past 2 Weeks (ALXN)
Comtex SmarTrend(R) - Mon May 12, 11:37AM CDT
Two weeks ago on April 24th, 2014 Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings and analysts, on average, expected earnings of $1.26 on sales of $560.7 million. The company actually reported EPS of $1.53 on sales of $566.6 million, beating EPS estimates by $0.27 and beating revenue estimates by $5.9 million. Shares of Alexion Pharmaceuticals have slipped from $156.01 to $152.87, representing a loss of 2.0%, since the company reported earnings 18 days ago.

Alnylam Up on Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:50AM CDT
Alnylam Pharma's (ALNY) shares were up ever since it announced its first quarter-results on May 8.

Visualizing Biotech P/E Compression and Why It's a Buy Signal
at The Street - Mon May 12, 9:19AM CDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.

Shares Continue to fall on Emergent BioSolutions' Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:10AM CDT
Shares of Emergent BioSolutions (EBS) have been on the way down since it reported wider first quarter 2014 loss.

Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:50AM CDT
Orexigen Therapeutics reported a net loss of 23 cents per share in the first quarter of 2014.

Dendreon Falls on Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:40AM CDT
Dendreon (DNDN) reported first-quarter 2014 lossof 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents.

Spectrum Pharma Up on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:00AM CDT
Spectrum Pharma's (SPPI) first quarter 2014 earnings of a penny per share were flat year over year.

XOMA Posts Wider Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 3:00PM CDT
XOMA Corporation (XOMA) posts wider-expected loss in the first quarter of 2014.

Anacor Reports Wider-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 1:40PM CDT
Shares of Anacor Pharma (ANAC) fell 9.2% after the company reported a wider loss.

Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share.

Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
PR Newswire - Fri May 09, 11:30AM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:

After The Biotech Sell-off, How Will Investors Treat Alexion Pharmaceuticals?
at Investor's Business Daily - Fri May 09, 11:03AM CDT
Today we'll check in on Alexion Pharmaceuticals (ALXN). It currently has only one FDA-approved drug, Soliris, which is used to treat two types of rare blood disorders. And it doesn't come cheap. The price tag is around $400,000 a year. Alexion is...

Wider-Than-expected Loss at NPS Pharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 11:00AM CDT
Shares of NPS Pharma (NPSP) declined following the reduced outlook on Gattex.

Medivation Q1 Loss Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 9:10AM CDT
Although Medivation (MDVN) missed expectations, Xtandi's performance was strong and guidance was raised.

Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:40AM CDT
Jazz Pharmaceuticals reported first quarter 2014 adjusted (including stock-based compensation expense and depreciation) earnings of $1.51 per share.

Avanir Loss In Line with Ests, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:00PM CDT
Avanir Pharma (AVNR) reported second quarter fiscal 2014 net loss per share of 8 cents, in line with the Zacks Consensus Estimate.

J&J /Gilead HCV Combo Drug Filed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:55PM CDT
Johnson & Johnson (JNJ) is seeking to expand the label of Olysio.

Myriad Genetics Drops despite Earnings, Revs Beat; Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 2:00PM CDT
Myriad Genetics (MYGN) reported EPS of 60 cents in the third quarter of fiscal 2014.

Regeneron Beats on Earnings, Revenues in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:27PM CDT
Regeneron (REGN) beat on earnings and revenues in the quarter.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....